- Desmopressin plus anticholinergic agent (AA) and desmopressin plus alarm have better efficacy than monotherapies for treating pediatric monosymptomatic nocturnal enuresis (MNE).
Why this matters
- MNE affects 15%-20% of children aged 5 years and 1%-2% of adolescents.
- Pooled estimates showed the treatment success rate for desmopressin plus AA was higher than that for monotherapy with desmopressin or alarm alone:
- desmopressin: OR, 0.27 (95% CI, 0.11-0.62); and
- alarm: OR, 0.29 (95% CI, 0.13-0.61).
- The success rate for desmopressin plus alarm was higher than for alarm monotherapy:
- alarm: OR, 0.52 (95% CI, 0.30-0.90).
- Success rates for desmopressin plus alarm and desmopressin plus AA were not significantly different.
- Researchers analyzed 18 randomized controlled trials comparing desmopressin, alarm, desmopressin plus alarm, and desmopressin plus AA (N=1649).
- Funding: None disclosed.
- MNE has many causes; patients may respond differently to the same treatment.
- Researchers included 3 AAs (tolterodine [eg, Detrol], oxybutynin [eg, Oxytrol], and propiverine) in the desmopressin plus AA treatment group.